Acute myeloblastic leukemia (ANLL-M2) with t(8;21)(q22;q22) variant expressing lymphoid but not myeloid surface antigens with a high number of G-CSF receptors

doi:10.1016/0145-2126(93)90026-H

Leukemia Research

Volume 17, Issue 4, April 1993, Pages 375-377

https://doi.org/10.1016/0145-2126(93)90026-H Get rights and content

Abstract

Leukemic cells from an 8-year-old girl with ANLL-M2 expressed precursor B-cell antigen CD19, but none of the myeloid antigens CD11b, CD13, CD14 and CD33. After culture, the cells expressed CD11b and CD13. The cells carried a high number of granulocyte colony-stimulating factor (G-CSF) receptors. In chromosome analysis, metaphase cells were obtained only in the case of culture with G-CSF. The karyotype was a variant of t(8;21)(q22;q22). Southern blot analysis revealed rearrangement of the AMLI gene located on chromosome 21.

These observations may suggest that even without myeloid surface antigens and with precursor B-cell antigen, ANLL-M2 with t(8;21)(q22;q22) has apparent myeloid characteristics.

References (9)

H. Tsuchiya et al.
G-CSF for chromosome analysis of myeloid leukemias and MDS
Cancer Genet. Cytogenet.
(1990)
T. Mojoti et al.
Granulocyte colony-stimulating factor (G-CSF) receptors on acute myeloblastic leukaemia cells and their relationship with the proliferative response to G-CSF in clonogenic assay
Br. J. Haemat.
(1991)
C.I. Civin
Human monomyeloid cell membrane antigens
Expl. Hemat.
(1990)
F. Lo Coco et al.
Immunophenotyping of acute myeloid leukemia: relevance of analysing different lineage-associated markers
Blut
(1989)

There are more references available in the full text version of this article.

Cited by (15)

Surrogate marker profiles for genetic lesions in acute leukemias
2010, Best Practice and Research: Clinical Haematology
Citation Excerpt :
The low expression of CD11a in t(8;21) AML is explained by the inhibition of CD11a promoter activity through the AML1/ETO fusion product [29]. Due to the high degree of myeloid immaturity, CD19POS t(8;21) cases can be misdiagnosed as ALL [2,28,30]. It is imperative, therefore, to test all cases of acute leukemia simultaneously for cCD22 (or cCD3) and myeloperoxidase in the same cell aliquot.
The basic hypothesis of surrogate marker profiles is that individual genetic lesions result in characteristic distortions of the cellular phenotype with some predictable consistency that can be exploited by sophisticated immunophenotyping. While cytogenetic and molecular aberrancies currently are accepted prognostic predictors in acute leukemias, single antigen expression and even antigenic profiles rarely impact on prognosis. However, increasingly, phenotypes are delineated which can serve as surrogates for underlying genetic aberrations of clinical importance. This development is of particular significance as antileukemic therapy becomes available that targets any component of the disturbed molecular pathways associated with these genetic lesions. This chapter will focus on established surrogate marker profiles, such as those for PML/RARα, AML1/ETO, FLT3-gene mutated acute lymphocytic leukemia (ALL), and BCR/ABL^POS ALL. As the list of therapeutic targets grows, the role of surrogate antigen profiles will grow, as they can predict for the efficacy of targeted approaches in lieu of expensive, time-consuming and not always accessible genetic analyses.
A novel translocation t(2;9)(q14;p12) in AML-M2 with an uncommon phenotype: Myeloperoxidase-positive and myeloid antigen-negative
2001, Leukemia Research
We report a case of acute myeloid leukemia (AML-M2) expressing myeloperoxidase (MPO) but no myeloid antigens. A few cases with this discordant phenotype have been reported and an association has been suggested between the lack of CD13 and CD33 in MPO positive AML and the presence of t(8;21). Cytogenetic and molecular analyses performed in our case showed 48,XY,+Y,+8,t(2;9)(q14;p12). We believe that combined approaches can contribute to detect particular AL cases like the present one, that confirms the heterogeneity of AML. However, further studies are needed to clarify the relationship between phenotypic aberrations and cytogenetic abnormalities.
AML1-MTG8 leukemic protein induces the expression of granulocyte colony- stimulating factor (G-CSF) receptor through the up-regulation of CCAAT/enhancer binding protein epsilon
2000, Blood
Citation Excerpt :
This difference in response to G-CSF between AML1-MTG8–expressing cells and G-CSFR–expressing cells suggests that additional factor(s) may be required for the continuous proliferation of cells and for the inhibition of morphologic terminal differentiation. Case reports have shown that high expression levels of G-CSFR can be found in leukemic cells from M2 AML patients.49, 50 To determine the relationship between AML with a t(8;21) translocation and G-CSFR expression, we measured G-CSFR activity in leukemic cells from M2 AML patients who were positive or negative for t(8;21).
The t(8;21) translocation is one of the most frequent chromosomal abnormalities associated with acute myeloid leukemia (AML). In this translocation, the AML1 (CBFA2/PEBP2aB) gene is disrupted and fused to the MTG8 (ETO) gene. The ectopic expression of the resulting AML1-MTG8 fusion gene product in L-G and 32Dcl3 murine myeloid precursor cells stimulates cell proliferation without inducing morphologic terminal differentiation into mature granulocytes in response to granulocyte-colony stimulating factor (G-CSF). This study found that the ectopic expression of AML1-MTG8 elevates the expression of the G-CSF receptor (G-CSFR). Analysis of the promoter region of the G-CSFR gene revealed that up-regulation of G-CSFR expression by AML1-MTG8 does not depend on the AML1-binding sequence, but on the C/EBP (CCAAT/enhancer binding protein) binding site. The results suggest that the overproduction of G-CSFR is at least partly mediated by C/EBPɛ, whose expression is activated by AML1-MTG8. The ectopic expression of G-CSFR in L-G cells induced cell proliferation in response to G-CSF, but did not inhibit cell differentiation into mature neutrophils. Overexpression of C/EBPɛ in L-G cells also stimulated G-CSF–dependent cell proliferation. High expression levels of G-CSFR were also found in the leukemic cells of AML patients with t(8;21). Therefore, G-CSF–dependent cell proliferation of myeloid precursor cells may be implicated in leukemogenesis.
Acute myeloblastic leukemia (AML-M2) expressing CD19 B-cell lymphoid antigen without myeloid surface antigens
1994, Leukemia Research
Flow Cytometry of Hematological Malignancies: Second Edition
2021, Flow Cytometry of Hematological Malignancies: Second Edition
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: Clinical perspective and significance
2018, Journal for ImmunoTherapy of Cancer

View all citing articles on Scopus

View full text

Concise reportAcute myeloblastic leukemia (ANLL-M2) with t(8;21)(q22;q22) variant expressing lymphoid but not myeloid surface antigens with a high number of G-CSF receptors

Abstract

Cancer Genet. Cytogenet.

Br. J. Haemat.

Expl. Hemat.

Immunophenotyping of acute myeloid leukemia: relevance of analysing different lineage-associated markers

Blut

Concise report
Acute myeloblastic leukemia (ANLL-M2) with t(8;21)(q22;q22) variant expressing lymphoid but not myeloid surface antigens with a high number of G-CSF receptors